Paper Details

  1. Home
  2. Paper Details

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

Author: ForbesAlastair, HeinzeHartmut, IyerKishore, JeppesenPalle B, JoelssonBo, MessingBernard, O'keefeStephen J D, PertkiewiczMarek, SeidnerDouglas L

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This prospective study determined whether teduglutide reduces parenteral support in patients with short bowel syndrome with intestinal failure (SBS-IF).
Paper Details　
Original Abstract of the Article :
Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion. These factors could increase fluid and nutrient absorption in patients with short bowel syndrome with intestina...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.gastro.2012.09.007

データ提供：米国国立医学図書館（NLM）

Teduglutide: A Promising Therapy for Short Bowel Syndrome with Intestinal Failure

Short bowel syndrome with intestinal failure (SBS-IF) presents a significant challenge for patients, often requiring long-term parenteral support. This study investigates the potential of teduglutide, a glucagon-like peptide 2 analogue, to reduce the need for parenteral support in SBS-IF. The authors conducted a prospective study to evaluate the impact of teduglutide on intestinal structure and function, finding that it significantly reduced the need for parenteral support in patients with SBS-IF. This research highlights the potential of teduglutide as a promising therapy for improving intestinal function and reducing reliance on parenteral support.

Teduglutide's Role in Intestinal Regeneration

The study reveals that teduglutide can significantly improve intestinal structure and function in patients with SBS-IF, leading to increased fluid and nutrient absorption. This finding underscores the potential of teduglutide in promoting intestinal regeneration and reducing the need for parenteral support, improving quality of life for SBS-IF patients.

Navigating the Challenges of SBS-IF

This research offers hope for patients with SBS-IF, providing a potential therapeutic option to reduce reliance on parenteral support and improve intestinal function. This study contributes to the ongoing effort to develop effective therapies for this challenging condition, enhancing the quality of life for patients.

Dr. Camel's Conclusion

Think of teduglutide as a life-giving oasis in the vast and challenging desert of SBS-IF. This research shows that teduglutide can help restore intestinal function, allowing patients to thrive and live more fulfilling lives. It's a testament to the power of scientific innovation in finding solutions to some of the most complex health challenges.

Date :
  1. Date Completed 2013-04-04
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

22982184

DOI: Digital Object Identifier

10.1053/j.gastro.2012.09.007

Related Literature

Article Analysis
・Effects of teduglutide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.